|
|
Vaccine Detail
|
Dendritic Cell Tumor Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Dendritic Cell Tumor Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: Intradermal injection (i.d.)
- Description: This is a vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. (NCIT_C1987) This vaccine is used to treat diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). It is made with the patient's own white blood cells and peptide-pulsed dendritic cells, which may help the body build an effective immune response to kill tumor cells. It is combined with immunotherapy monoclonal antibodies, such as nivolumab and ipilimumab, which also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (NCT05457959)
|
| Host Response |
|
|
| References |
NCIT_C1987: Dendritic Cell Tumor Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987]
NCT05457959: Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant [https://clinicaltrials.gov/study/NCT05457959]
|
|
